⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
BIRC6 Inhibition (LNP-ASO)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-23 — Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.: Preclinical mouse study plus ex vivo human HSC work: antibody-conjugated LNP-ASOs against BIRC6 disrupt a newly mapped bone-marrow Treg–cAMP–PKA–CREB–BIRC6 axis that shields aged HSCs from apoptosis, reversing HSC aging and immunosenescence in middle-aged mice and showing activity in middle-aged human HSCs. [animal-model] (novelty: 4)
Open questions
Related
Contributing findings
Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.
23-sep-2026
novelty 4
per-area 4
strengthens